Patient Square Capital LP Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Patient Square Capital LP bought a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 235,498 shares of the biopharmaceutical company’s stock, valued at approximately $2,049,000. Ocular Therapeutix accounts for 0.8% of Patient Square Capital LP’s holdings, making the stock its 10th largest position. Patient Square Capital LP owned 0.15% of Ocular Therapeutix as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Atlas Capital Advisors LLC purchased a new stake in Ocular Therapeutix during the second quarter worth $34,000. Amalgamated Bank lifted its holdings in shares of Ocular Therapeutix by 37.9% during the 2nd quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,481 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Ocular Therapeutix by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 1,015 shares during the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of Ocular Therapeutix during the 3rd quarter valued at $70,000. Finally, Algert Global LLC purchased a new stake in shares of Ocular Therapeutix during the 2nd quarter valued at $69,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Price Performance

Shares of Ocular Therapeutix stock opened at $9.49 on Wednesday. Ocular Therapeutix, Inc. has a twelve month low of $2.88 and a twelve month high of $11.77. The business has a 50-day moving average price of $10.02 and a 200 day moving average price of $8.33. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. The firm has a market cap of $1.49 billion, a PE ratio of -7.19 and a beta of 1.19.

Insider Activity at Ocular Therapeutix

In related news, insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $9.01, for a total value of $26,561.48. Following the transaction, the insider now owns 269,059 shares of the company’s stock, valued at $2,424,221.59. This represents a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 3.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have recently commented on OCUL shares. Robert W. Baird decreased their price objective on Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday. Finally, Scotiabank assumed coverage on Ocular Therapeutix in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.71.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.